POPULATION PK AND EXPOSURE-RESPONSE ANALYSES OF APREMILAST IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0
|
作者：
Kassir, N. [1 ]
Savant, I. [2 ]
Mouksassi, M. S. [1 ]
Marier, J. F. [1 ]
Zhu, W. [2 ]
Lau, H. [2 ]
机构：
[1] Pharsight Corp, Montreal, PQ, Canada
[2] Celgene Corp, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [11] Population PK and Exposure-Response Analyses of Icatibant in Pediatric Patients for the Treatment of Hereditary Angioedema
    Marier, J. F.
    Jomphe, Claudia
    Schranz, Jennifer
    Martin, Patrick
    Wang, Yi
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S59 - S60
  • [12] ABATACEPT POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES FOR DOSE RECOMMENDATION OF SC AND IV ABATACEPT IN PATIENTS WITH PSORIATIC ARTHRITIS.
    Li, X.
    Passarell, J. A.
    Morris, D.
    Murthy, B.
    Girgis, I. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S77 - S77
  • [13] Adjunctive Perampanel in Pediatric Patients with Epilepsy: Population Pharmacokinetic (PK) and Exposure-Response Analyses
    Majid, Oneeb
    Reyderman, Larisa
    Ferry, Jim
    Hussein, Ziad
    NEUROLOGY, 2019, 92 (15)
  • [14] Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis
    Thakre, N.
    Goebel, A.
    D'Cunha, R.
    Winzenborg, I.
    Liu, W.
    Pang, Y.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1831 - I1831
  • [15] Exposure-response analyses of tigecycline tolerability in healthy subjects
    Passarell, Julie
    Ludwig, Elizabeth
    Liolios, Kathryn
    Meagher, Alison K.
    Grasela, Thaddeus H.
    Babinchak, Timothy
    Ellis-Grosse, Evelyn J.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 65 (02) : 123 - 129
  • [16] Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials
    Muensterman, Elena
    Engelhardt, Benjamin
    Gopalakrishnan, Sathej
    Anderson, Jaclyn K.
    Mohamed, Mohamed-Eslam F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (01): : 267 - 278
  • [17] Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis
    Kavanaugh, Arthur
    Gladman, Dafna D.
    Gomez-Reino, Juan J.
    Hall, Stephen
    Lespessailles, Eric
    Mease, Philip J.
    Schett, Georg
    Pari, Maria
    Teng, Lichen
    Wollenhaupt, Juergen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB114 - AB114
  • [18] Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies
    Menon, Sujatha
    Shoji, Satoshi
    Tsuchiwata, Shinichi
    Fallon, Lara
    Kanik, Keith
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (03): : 369 - 377
  • [19] BUDGET IMPACT OF APREMILAST FOR ACTIVE PSORIATIC ARTHRITIS IN THE UK
    Mughal, F.
    Damera, V
    Gagnon, J.
    VALUE IN HEALTH, 2016, 19 (07) : A532 - A532
  • [20] PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST
    Mease, Philip J.
    Behrens, Frank
    Gladman, Dafna D.
    Kavanaugh, Arthur
    Brunori, Michele
    Teng, Lichen
    Guerette, Benoit
    Queiro, Ruben
    Ogdie, Alexis
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 916 - 917
12345